The mass spectrometry platform of the Pharmacology Research Unit (URP) is a new platform specialized in the monitoring assay of pharmaceutical molecules in different biological matrices that are part of the common scientific platforms of the CHU Sainte-Justine Research Center.
In January 2021, we launched an integrated pharmacology platform, supported in part by the CHU Sainte-Justine Research Center to assist researchers in pharmacokinetic studies involved in clinical trials or for small molecule assay in translational research projects.
We have dedicated expert staff and state-of-the-art equipment such as high-performance tandem mass spectrometers (LC-MS/MS), triple quad Agilent model 6410 and 64560, to assist your drug monitoring in a pediatric context of limited sampling volume.
We have extensive experience in dosing components (e.g., ruxolitinib, trametinib, imatinib, busulfan, cyclosporine, tacrolimus), for different parameters (Cmax, Cmin, free fraction) and vouch our full support in making this expertise available to the entire research community.
Equipments
- 3 HPLC series 1260 Agilent
- 2 Triple quad Agilent 6410 and 6460
Services
- Development of methods for pharmacological assays in different biological matrices (e.g. plasma, breast milk)
- Pharmacological assays using existing methods in the literature or in the clinical laboratory setting
- Consulting service to initiate a project
Clientele
Academic, pharmaceutical or biotechnology industries interested in pharmacology.
Training
Upcoming – Extraction method
Financial partners
- Grandir en santé Fund
- Canada Foundation for Innovation (CFI)
- CHU Sainte-Justine Foundation
Partner institutions
- OPTILAB
- CHU Sainte-Justine
Contact person
Audrey Denoncourt, LC-MS/MS specialist
audrey.denoncourt.hsj@ssss.gouv.qc.ca
Others
Yves Théorêt
yves.theoret@umontreal.ca
Jean-Marie Leclerc
jean-marie.leclerc@umontreal.ca
Valérie Villeneuve
valerie.villeneuve.hsj@ssss.gouv.qc.ca
Price List
| Service* |
| Faisability Study |
Personalized prices for each project according to the number of molecules to be assayed, the complexity of the matrix, the number of samples, the duration of the project and the researcher's affiliation (internal, academic, private). |
| Bioanalytical Method Development |
| Partial or Complete Validation of the Bioanalytical Method (Internal SOP or FDA) |
| Preparation and Extraction of the molecules to monitor in the samples (liquid-liquid or solid phase extraction (LLE or SPE)) |
| Determination of the nominal mass per direct injection |
| Analysis of the intact mass by direct injection |
| *The client understands and agrees that the services of the platform should not be used to make a clinical diagnosis as part of standard patient care. |